Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Concentration-controlled zidovudine therapy.

Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, Remmel RP, Erice A, Balfour HH Jr.

Clin Pharmacol Ther. 1998 Sep;64(3):331-8.

PMID:
9757157
[PubMed - indexed for MEDLINE]
2.

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.

Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC.

AIDS. 2002 Mar 8;16(4):551-60.

PMID:
11872998
[PubMed - indexed for MEDLINE]
3.

Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.

Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP.

AIDS. 2000 Sep 29;14(14):2137-44.

PMID:
11061655
[PubMed - indexed for MEDLINE]
4.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team.

JAMA. 2001 Mar 7;285(9):1155-63. Erratum in: JAMA 2001 Jun 13;285(22):2858.

PMID:
11231744
[PubMed - indexed for MEDLINE]
5.

Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy.

Acosta EP, Henry K, Page LM, Erice A, Balfour HH Jr, Fletcher CV.

Pharmacotherapy. 1997 May-Jun;17(3):424-30.

PMID:
9165546
[PubMed - indexed for MEDLINE]
6.

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.

Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC, Fletcher CV.

Antimicrob Agents Chemother. 2001 Jan;45(1):236-42.

PMID:
11120972
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.

Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.

AIDS. 2000 Apr 14;14(6):671-81. Erratum in: AIDS 2000 Jun 16;14(9):1295.

PMID:
10807190
[PubMed - indexed for MEDLINE]
8.

Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.

Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K.

JAMA. 2000 Jan 26;283(4):492-8.

PMID:
10659875
[PubMed - indexed for MEDLINE]
9.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;6:CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
[PubMed - indexed for MEDLINE]
10.

Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Bhana N, Ormrod D, Perry CM, Figgitt DP.

Paediatr Drugs. 2002;4(8):515-53. Review.

PMID:
12126455
[PubMed - indexed for MEDLINE]
11.

Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D.

Antiviral Res. 2000 Jan;45(1):47-58.

PMID:
10774589
[PubMed - indexed for MEDLINE]
12.

Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort.

Becker SL, Raffanti SR, Hansen NI, Fusco JS, Fusco GP, Slatko GH, Igboko EF, Graham NM; Collaborations in HIV Outcomes Research--US (CHORUS) Program Team.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):72-81.

PMID:
11176271
[PubMed - indexed for MEDLINE]
13.

Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.

Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF.

Antivir Ther. 2010;15(2):185-92. doi: 10.3851/IMP1514.

PMID:
20386073
[PubMed - indexed for MEDLINE]
14.

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.

DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K, Madison SJ; EPV20001 International Study Team.

Clin Infect Dis. 2004 Aug 1;39(3):411-8. Epub 2004 Jul 15.

PMID:
15307010
[PubMed - indexed for MEDLINE]
Free Article
15.

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H.

JAMA. 1996 Jul 10;276(2):118-25.

PMID:
8656503
[PubMed - indexed for MEDLINE]
16.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

JAMA. 2006 Aug 16;296(7):769-81.

PMID:
16905783
[PubMed - indexed for MEDLINE]
17.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

PMID:
19282782
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.

Curr Med Res Opin. 2004 Jul;20(7):1103-14.

PMID:
15265255
[PubMed - indexed for MEDLINE]
19.

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.

Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G.

AIDS. 1998 Nov 12;12(16):F197-202.

PMID:
9833847
[PubMed - indexed for MEDLINE]
20.

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.

Anderson PL, Kakuda TN, Kawle S, Fletcher CV.

AIDS. 2003 Oct 17;17(15):2159-68.

PMID:
14523272
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk